

## Influenza Vaccines for Healthy Children aged 2 through 8 Years—Review of Comparative Studies of Live Attenuated Influenza Vaccine (LAIV) and Inactivated Influenza Vaccine (IIV)

### METHODS

**Background:** An adaptation of Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methods [1] was used to evaluate relative benefits and harms of live attenuated influenza vaccine (LAIV) and inactivated influenza vaccine (IIV) for healthy children aged 2 through 8 years. As of the 2013-14 influenza season, the Advisory Committee on Immunization Practices (ACIP) recommendations stated that healthy children in this age group may receive either vaccine, with no preferential recommendation for one over the other. Outcome values and evidence of benefits and harms were reviewed in accordance with GRADE methods as adopted by the ACIP [1]. The primary policy question was **“Should LAIV be recommended preferentially over IIV for healthy children aged 2 through 8 years?”**

While several individual studies noted greater relative efficacy of LAIV relative to TIV among children [2-4], most studies conducted among adults have generally noted either similar efficacy or greater relative efficacy of IIV [5-11]. Because it is unclear at what age the greater relative efficacy of LAIV begins to decline, and given considerations to the feasibility of implementation of a potential change in program, this assessment focused on younger children. The rationale for the selected age range included the following considerations: 1) LAIV is not licensed in the U.S. for children under 2 years of age [12], and 2) 8 years is the current upper age limit for consideration of whether a child needs one or two doses of influenza vaccine [13], and was selected for programmatic consistency.

**Identification and valuation of outcome measures:** Efficacy and safety outcomes were discussed within the ACIP Influenza Work Group. Outcomes valued as “critical” or “important” [1] to policy decisions are summarized in Table 1. One initially selected outcome, “medically attended wheezing”, was replaced with “medically significant wheezing” after literature review revealed data were available for this similar outcome. Three initially selected safety outcomes “febrile seizure”, “immediate hypersensitivity/anaphylaxis”, and “Guillain-Barré syndrome” were noted to be sufficiently rare that it would not be possible to draw meaningful comparisons between the two vaccines. As a proxy outcome intended to enumerate very rare but severe events, these outcomes were replaced with “any related serious adverse event (SAE)”. Two additional outcomes, “respiratory symptoms” and “other neurologic outcomes” were not sufficiently specific to permit data collection.

**Evidence retrieval:** Prior to literature retrieval, study inclusion/exclusion criteria were defined. Included studies pertained to healthy children (i.e., did not specifically seek to enroll children with medical conditions conferring higher risk of complications due to influenza), evaluated

vaccines that were U.S.-licensed or were similar to U.S.-licensed products, and included both LAIV and IIV arms (so as to permit comparison within the same population and influenza season). Excluded studies included those assessing vaccines dissimilar from U.S.-licensed products (e.g., virosomal, whole-virus, and adjuvanted vaccines and Russian-manufactured LAIV), those exclusively of monovalent influenza A(H1N1)pdm 2009 vaccines, those for which inactivated vaccine antigen content was characterized in units other than micrograms of hemagglutinin (HA), those for which all participants were outside the indicated age range for either vaccine, and those for which outcomes were based upon ICD-9 codes (without clinical or laboratory evaluation). For efficacy outcomes, a total of five randomized trials [2-4, 14, 15] and six observational studies [16-21] were identified. Among the five randomized trials, three were excluded from the analysis: one in which not all influenza cases were laboratory confirmed [14], one of children 1 through 15 years of age for which age-stratified data were not available [15], and one of children 6 through 17 years of age for which age stratified data were not available and for which having a diagnosis of asthma was an inclusion criterion [3]. Among the six observational studies, one study of children 5 through 18 years of age for which age stratified data were not available for the outcome of interest was excluded [21]. The efficacy assessment thus included two randomized trials [2, 4] and five observational studies [16-20]. For safety outcomes, observational studies were not included in GRADE analyses because of concerns that differences in the health status of the populations receiving LAIV and IIV might affect safety endpoints. Of the 5 randomized trials identified during the efficacy outcome search, 2 included safety outcomes in the appropriate age group [2, 4].

**Evidence assessment:** Quality of available evidence was graded in terms of risk of bias, indirectness, imprecision, and inconsistency and was assessed as “High”, “Moderate”, “Low”, or “Very Low” for each outcome [1]. For randomized studies, when summarizing results for outcomes in which denominators reported individual participants, pooled weighted risk ratios were calculated using a random-effects model. For outcomes for which the denominator was expressed as person-time, risk ratios were calculated using the inverse variance method. For observational studies, odds ratios (ORs) were transformed by taking the natural logarithm and pooling log(OR)s and standard errors using the inverse variance method.

## RESULTS

### Assessment of Benefits and Harms

**Table 1: Outcomes valued as “Critical” or “Important” to policymaking by the ACIP Influenza Work Group**

<b>Outcome</b>	<b>Importance</b>	<b>Data Available</b>
<b>Benefits (Efficacy)</b>		
Laboratory-confirmed influenza	Critical	Yes
Influenza-associated mortality	Critical	No
Influenza-associated hospitalization	Critical	Yes
Medically attended acute respiratory illness	Critical	Yes
Influenza-like illness	Important	No
Influenza-associated acute otitis media	Important	Yes
<b>Harms (Safety)</b>		
Medically significant wheezing <sup>1</sup>	Critical	Yes
Immediate hypersensitivity/anaphylaxis <sup>2</sup>	Critical	No
Febrile seizure <sup>2</sup>	Critical	No
Guillain-Barre syndrome <sup>2</sup>	Critical	No
Respiratory symptoms <sup>4</sup>	Important	--
Other neurologic outcomes <sup>4</sup>	Important	--
Fever	Important	Yes
Any related SAE <sup>3</sup>	--	Yes

<sup>1</sup>Replaced medically attended wheezing.

<sup>2</sup>Rare events; insufficient frequency to permit comparison.

<sup>3</sup>Added as a means to potentially capture rare but serious events.

<sup>4</sup>Not sufficiently specific to permit assessment.

**Table 2: Characteristics of included studies**

<b>Studies</b>	<b>Design</b>	<b>Number of participants</b>	<b>Age group evaluated</b>	<b>Efficacy/ Effectiveness</b>	<b>Safety</b>
Ashkenazi, 2006 [2]	Randomized, open-label	2187	6 through 71 months <sup>1</sup> (1609 aged ≥2 years)	X	X
Belshe, 2007 [4]	Randomized, blinded, placebo-controlled	8352	6 through 59 months <sup>1</sup> (4166 aged ≥2 years)	X	X
Treanor, 2012 [16]	Observational, Test-negative case-control	49	2 through 8 years <sup>2</sup>	X	
Ohmit, 2013 [17]	Observational, Test-negative case-control	358	2 through 8 years <sup>2</sup>	X	
Fry, 2013 [18]	Observational, Test-negative case-control	559	2 through 8 years <sup>2</sup>	X	
Macintosh, 2013 [19]	Observational, Test-negative case-control	66	2 through 8 years <sup>2</sup>	X	
Eick-Cost, 2013 [20]	Observational, Test-negative case-control	195	2 through 8 years <sup>2</sup>	X	

<sup>1</sup>Data available for children aged 24 through 71 months for one outcome, laboratory-confirmed influenza, from a post-hoc meta-analysis of data from these two studies [22].

<sup>2</sup>Authors provided data specific to this age group

**Table 3: LAIV vs. IIV for healthy children aged 2-8 years: Benefits—Randomized studies**

Outcome (Studies, n) Value	Risk of Bias	Inconsistency	Indirectness	Imprecision	Outcome events		Effect		Quality
					With LAIV	With IIV	RR [95% CI]	Risk Difference per 1000 with LAIV	
Laboratory-confirmed influenza (2) <i>Critical</i>	Not serious <sup>1</sup>	Not serious	Not serious	Not serious	182/4966	398/4971	0.46 [0.39-0.54]	43 fewer [37-49 fewer]	1 High
Laboratory-confirmed influenza--24-71 month olds <sup>2</sup> (2) <i>Critical</i>	Not serious <sup>1</sup>	Not serious	Not serious	Not serious	117/2873	251/2902	0.47 [0.38-0.58]	46 fewer [36-54 fewer]	1 High
Influenza-associated hospitalization (1) <i>Critical</i>	Not serious <sup>1</sup>	Not serious	Serious <sup>3</sup>	Serious <sup>4</sup>	12/1048	11/1034	1.08 [0.48-2.43]	1 more [6 fewer-15 more]	3 Low
Influenza-associated acute otitis media (2) <i>Important</i>	Not serious <sup>1</sup>	Not serious	Not serious	Not serious	28/4964	60/4970	0.47 [0.30-0.73]	6 fewer [3-8 fewer]	1 High
Outcome (Studies, n) Value	Risk of Bias	Inconsistency	Indirectness	Imprecision	Outcome events		Effect		Quality
					With LAIV <sup>5</sup>	With IIV	Adj. OR [95% CI]		
MAARI (1) <i>Critical</i>	Not serious <sup>1</sup>	Not serious	Serious	Not serious	878/72476	949/71337	0.91 [0.77-1.08]		2 Moderate

ABBREVIATIONS: adj. OR, adjusted odds ratio; CI, confidence interval; MAARI, Medically attended acute respiratory illness.

<sup>1</sup> One trial was open-label [2].

<sup>2</sup> Meta-analysis including these two trials contained data restricted to those children aged 2 years and older.

<sup>3</sup> Hospitalizations were for influenza-like respiratory illness that prompted culture, rather than laboratory-confirmed influenza

<sup>4</sup> Wide confidence interval; includes 1.0 and exceeds 0.75 in lower bound and 1.25 in upper bound.

<sup>5</sup> Denominator was surveillance-days

**Table 4: LAIV vs. IIV for healthy children aged 2-8 years: Benefits—Observational studies**

Outcome (Studies, n) Value	Risk of Bias	Inconsistency	Indirectness	Imprecision	Outcome events		Effect	Quality
					With LAIV	With IIV	Adj. OR [95% CI]	
Laboratory-confirmed influenza <sup>1</sup> (5) <b>Critical</b>	Not serious	Not serious	Not serious	Serious <sup>2</sup>	83/288	257/939	0.74 [0.50-1.08]	4 [Very Low]

<sup>1</sup>Authors provided data for subgroup of children aged 2 through 8 years.

<sup>2</sup>Wide confidence interval includes 1.0 and exceeds 0.75 in lower bound.

**Table 5: LAIV vs. IIV for healthy children aged 2-8 years: Harms—Randomized studies**

Outcome (Studies, n) Value	Risk of Bias	Inconsistency	Indirectness	Imprecision	Outcome events		Effect		Quality
					With LAIV	With IIV	RR [95% CI]	Risk Difference per 1000 with LAIV	
Medically significant wheezing, 42 days-- Following dose 1, vaccine-naïve <sup>1</sup> (1) <b>Critical</b>	Not serious	Not serious	Not serious	Serious <sup>2</sup>	19/1521	14/1520	1.36 [0.68-2.69]	3 more [3 fewer-16 more]	2 Moderate
Medically significant wheezing, 42 days-- Following dose 1, previously vaccinated <sup>1</sup> (1) <b>Critical</b>	Not serious	Not serious	Not serious	Serious <sup>2</sup>	12/666	14/678	0.87 [0.41-1.87]	3 fewer [12 fewer-18 more]	2 Moderate
Medically significant wheezing, 42 days-- Following dose 2, not previously vaccinated <sup>1</sup> (1) <b>Critical</b>	Not serious	Not serious	Not serious	Serious <sup>3</sup>	16/1424	28/1439	0.58 [0.31-1.06]	8 fewer [13 fewer-1 more]	2 Moderate
Fever, days 0-10-- ≥38.6°C or ≥38.9°C <sup>4</sup> (2) <b>Critical</b>	Not Serious <sup>5</sup>	Not serious	Not serious	Serious <sup>3</sup>	189/5095	211/5068	0.89 [0.73-1.08]	5 fewer [11 fewer-3 more]	2 Moderate
Any related serious adverse event (SAE) (2) (Not valued)	Not Serious <sup>5</sup>	Not serious	Not serious	Serious <sup>2</sup>	8/5280	9/5289	0.90 [0.34-2.37]	0 fewer [1 fewer-2 more]	2 Moderate

<sup>1</sup>Data limited to children aged 24 through 59 months.

<sup>2</sup>Wide confidence interval; includes 1.0 and exceeds 0.75 in lower bound and 1.25 in upper bound.

<sup>3</sup>Wide confidence interval; includes 1.0 and exceeds 0.75 in lower bound.

<sup>4</sup>Fever reported differently in the two studies.

<sup>5</sup>One trial was open-label.

**Table 6: Evidence summary.**

Focus	Outcome (Importance)	Design (n)	Findings (difference between LAIV and IIV)	Evidence Quality by Outcome	Overall Evidence Quality
Benefits	Laboratory-confirmed influenza <b>CRITICAL</b>	RCT (2)	Lower risk with LAIV	1 (High)	2 (Moderate) <sup>1</sup>
		OBS (5)	No difference	4 (Very low)	
	Influenza-associated hospitalization <b>CRITICAL</b>	RCT (1)	No difference	3 (Low)	
	Medically attended acute respiratory illness <b>CRITICAL</b>	RCT (1)	No difference	2 (Moderate)	
	Acute otitis media <b>IMPORTANT</b>	RCT (2)	Lower risk with LAIV	1 (High)	
Harms	Medically significant wheezing <b>CRITICAL</b>	RCT (1)	No difference	2 (Moderate)	2 (Moderate)
	Fever <b>IMPORTANT</b>	RCT (2)	No difference	1 (High)	
	Any related severe adverse event <b>IMPORTANT</b>	RCT (2)	No difference	2 (Moderate)	

<sup>1</sup>For Benefits, quality is taken to be “moderate” rather than “low” because available hospitalization data was downgraded for indirectness (respiratory illness-associated hospitalizations rather than influenza-associated hospitalizations), and because data were available for two other critical outcomes.

**Cost considerations:**

A formal cost analysis was not performed. Such analysis would be complex given the current spectrum of available influenza vaccine products available in the United States, and their widely variable costs. As of 2013-14, LAIV is available in the U.S. only as a quadrivalent vaccine, while IIV is available in both quadrivalent and trivalent formulations of highly differing cost. A cost effectiveness model compared LAIV3 and IIV3 for younger children and estimated a cost savings of USD\$45.80 for each child vaccinated with LAIV as compared with IIV [23]. It is unclear how applicable such an analysis is at present, given the recent availability of quadrivalent vaccines. Private sector prices listed in the 2014-15 Vaccines for Children (VFC) price list for trivalent IIVs range from \$7.65 to \$14.81/dose; those for quadrivalent IIV from \$14.90 to \$21.09/dose. The most highly priced quadrivalent IIV4 is similar in cost to LAIV at \$22.70 per dose (available at: <http://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html>).

**Table 7: Considerations for Formulating Recommendations**

Key factor	Comments
Evidence type for benefits and harms	<ul style="list-style-type: none"><li>• Overall evidence quality 2 (MODERATE) for efficacy and safety.</li><li>• Evidence lacking for some critical outcomes, such as influenza-associated mortality, febrile seizure, Guillain-Barré syndrome, immediate hypersensitivity</li><li>• Available studies not powered to detect rare but serious events</li></ul>
Balance between benefits and harms	<ul style="list-style-type: none"><li>• Benefits outweigh harms</li><li>• Modestly better efficacy of LAIV (~46 fewer cases of laboratory-confirmed influenza per 1000)</li><li>• No significant differences in rates of wheezing or fever</li></ul>
Value	<ul style="list-style-type: none"><li>• ACIP Influenza Work Group placed high value on prevention of laboratory-confirmed influenza</li></ul>
Cost-effectiveness	<ul style="list-style-type: none"><li>• Uncertainty regarding cost benefit given current available range of vaccines</li></ul>

## **LIMITATIONS**

- All data reviewed pertain to trivalent influenza vaccines. As of the 2013-14 season, all LAIV available in the United States is quadrivalent, and IIV is available in both trivalent and quadrivalent formulations. Quadrivalent vaccines met criteria for immunogenic non-inferiority compared to trivalent vaccines prior to licensure, and pre-licensure studies demonstrated similar safety profiles.
- It is as yet unknown whether greater relative efficacy is sustained with repeated vaccination/increasing age. Comparative studies of LAIV and IIV in adults generally have noted either that the two vaccines are similar in efficacy, or that IIV is somewhat more effective. The age or degree of previous seasonal vaccine exposure at which relative benefits of LAIV decline, or are no longer apparent, is not known. Available RCT data include children under 2 years of age; data excluding these children was only available for one outcome (laboratory-confirmed influenza). Moreover, available RCT data does not include children over 71 months of age. While the age or degree of previous seasonal vaccine exposure at which relative benefits of LAIV begins to decline is unknown, one additional comparative RCT of older children (aged 6 through 17 years) with asthma has also noted greater relative efficacy of LAIV [3].

Given these limitations, ongoing evaluation of the relative efficacy of current formulations of LAIV and IIV will be important.

## **SUMMARY**

Benefits outweigh harms. High value was placed on the prevention of laboratory-confirmed influenza. The Work Group recommended that when LAIV is available, it should be used for children aged 2 through 8 years (Category A).

## **References**

1. Ahmed, F., *U.S. Advisory Committee on Immunization Practices (ACIP) Handbook for Developing Evidence-based Recommendations: Version 1.2 [November 1, 2013]*. 2013, Centers for Disease Control and Prevention: Atlanta, GA.
2. Ashkenazi, S., et al., *Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections*. *Pediatr Infect Dis J*, 2006. **25**(10): p. 870-9.
3. Fleming, D.M., et al., *Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma*. *Pediatr Infect Dis J*, 2006. **25**(10): p. 860-9.
4. Belshe, R.B., et al., *Live attenuated versus inactivated influenza vaccine in infants and young children*. *N Engl J Med*, 2007. **356**(7): p. 685-96.
5. Monto, A.S., et al., *Comparative efficacy of inactivated and live attenuated influenza vaccines*. *N Engl J Med*, 2009. **361**(13): p. 1260-7.
6. Ohmit, S.E., et al., *Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines*. *N Engl J Med*, 2006. **355**(24): p. 2513-22.
7. Ohmit, S.E., et al., *Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines*. *J Infect Dis*, 2008. **198**(3): p. 312-7.
8. Wang, Z., et al., *Live attenuated or inactivated influenza vaccines and medical encounters for respiratory illnesses among US military personnel*. *JAMA*, 2009. **301**(9): p. 945-53.
9. Eick, A.A., et al., *Comparison of the trivalent live attenuated vs. inactivated influenza vaccines among U.S. military service members*. *Vaccine*, 2009. **27**(27): p. 3568-75.
10. Treanor, J.J., et al., *Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses*. *Vaccine*, 1999. **18**(9-10): p. 899-906.
11. Forrest, B.D., et al., *A prospective, randomized, open-label trial comparing the safety and efficacy of trivalent live attenuated and inactivated influenza vaccines in adults 60 years of age and older*. *Vaccine*, 2011. **29**(20): p. 3633-9.
12. MedImmune Vaccines, I., *Package Insert for FluMist Quadrivalent Intranasal Spray*, in Available at: <http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094047.htm>. 2013. p. 25.
13. *Prevention and control of seasonal influenza with vaccines. Recommendations of the Advisory Committee on Immunization Practices--United States, 2013-2014*, in *MMWR Recomm Rep*. 2013, Centers for Disease Control and Prevention. p. 1-43.
14. Clover, R.D., et al., *Comparison of heterotypic protection against influenza A/Taiwan/86 (H1N1) by attenuated and inactivated vaccines to A/Chile/83-like viruses*. *J Infect Dis*, 1991. **163**(2): p. 300-4.
15. Neuzil, K.M., et al., *Efficacy of inactivated and cold-adapted vaccines against influenza A infection, 1985 to 1990: the pediatric experience*. *Pediatr Infect Dis J*, 2001. **20**(8): p. 733-40.

16. Treanor, J.J., et al., *Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains*. Clin Infect Dis, 2012. **55**(7): p. 951-9.
17. Ohmit, S.E., et al., *Influenza Vaccine Effectiveness in the 2011-2012 Season: Protection Against Each Circulating Virus and the Effect of Prior Vaccination on Estimates*. Clin Infect Dis, 2013.
18. Centers for Disease, C. and Prevention, *Interim adjusted estimates of seasonal influenza vaccine effectiveness - United States, February 2013*. MMWR Morb Mortal Wkly Rep, 2013. **62**(7): p. 119-23.
19. MacIntosh, V.H., K.J. Tastad, and A.A. Eick-Cost, *Mid-season influenza vaccine effectiveness 2011-2012: a Department of Defense Global, Laboratory-based, Influenza Surveillance System case-control study estimate*. Vaccine, 2013. **31**(13): p. 1651-5.
20. Eick-Cost, A.A., et al., *Mid-season influenza vaccine effectiveness for the 2012-2013 influenza season*. MSMR, 2013. **20**(3): p. 15-6.
21. Halloran, M.E., et al., *Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004*. Vaccine, 2007. **25**(20): p. 4038-45.
22. Ambrose, C.S., et al., *The efficacy of intranasal live attenuated influenza vaccine in children 2 through 17 years of age: a meta-analysis of 8 randomized controlled studies*. Vaccine, 2012. **30**(5): p. 886-92.
23. Luce, B.R., et al., *Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States*. Vaccine, 2008. **26**(23): p. 2841-8.